Yagen

YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM). It is a gene-selective partial agonist of the androgen receptor (AR) and does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR. The drug has anabolic activity in vitro in C2C12 myoblasts and shows greater potency than dihydrotestosterone (DHT) in this regard.

Chemistry

YK-11 is a synthetic steroidal SARM. It is derived from testosterone and has a very similar chemical structure. The compound is classified as a gene-selective partial agonist of the androgen receptor (AR), which is the primary biological target of androgens like testosterone and dihydrotestosterone.

Pharmacology

YK-11 shows anabolic activity in vitro in C2C12 myoblasts, which are a type of muscle cell. It has been found to be a partial agonist of the androgen receptor with full selectivity. The drug does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR. This is in contrast to other SARMs, which are full agonists of the androgen receptor.

Research

Research into YK-11 is still in its early stages, and much of what is known about the drug comes from in vitro studies. More research is needed to fully understand the effects of YK-11 in humans.

Safety

The safety of YK-11 is currently unknown. As a synthetic steroidal SARM, it may have similar side effects to other SARMs. These can include suppression of natural testosterone production, mood changes, and liver damage. However, more research is needed to confirm these potential side effects.

See also

• Selective androgen receptor modulator
• Androgen receptor
• Dihydrotestosterone
• Testosterone

Yagen Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski